We are live on ! Find out more
Charles Schwab

Charles Schwab Portfolio holdings

AUM $654B
1-Year Est. Return 26.35%
 

Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.

This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+26.35%
3 Year Est. Return
+83.88%
5 Year Est. Return
+111.55%
10 Year Est. Return
+435.02%
AUM
$394B
AUM Growth
+$44.6B
Cap. Flow
+$6.63B
Cap. Flow %
1.68%
Top 10 Hldgs %
19.2%
Holding
3,619
New
44
Increased
2,356
Reduced
681
Closed
81

Sector Composition

Rank Sector Weight
1 Technology 23.03%
2 Financials 12.41%
3 Healthcare 11.8%
4 Consumer Discretionary 10.03%
5 Industrials 9.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NAUT icon
3151
Nautilus Biotechnolgy
NAUT
$113M
$408K ﹤0.01%
136,354
-9,124
-6% -$26.1K
BLUE
3152
DELISTED
bluebird bio
BLUE
$406K ﹤0.01%
14,700
+115
+0.8% +$7.01K
VRCA icon
3153
Verrica Pharmaceuticals
VRCA
$89.3M
$405K ﹤0.01%
5,536
PWOD
3154
DELISTED
Penns Woods Bancorp
PWOD
$404K ﹤0.01%
17,926
GWRS icon
3155
Global Water Resources
GWRS
$219M
$401K ﹤0.01%
30,651
MG icon
3156
Mistras Group
MG
$582M
$400K ﹤0.01%
54,631
MACK
3157
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$397K ﹤0.01%
29,628
AOMR
3158
Angel Oak Mortgage REIT
AOMR
$209M
$397K ﹤0.01%
37,444
DC icon
3159
Dakota Gold
DC
$856M
$396K ﹤0.01%
151,186
LCTX icon
3160
Lineage Cell Therapeutics
LCTX
$281M
$396K ﹤0.01%
363,215
EZPW icon
3161
Ezcorp Inc
EZPW
$1.68B
$390K ﹤0.01%
44,675
+8,922
+25% +$74.9K
TNYA icon
3162
Tenaya Therapeutics
TNYA
$173M
$387K ﹤0.01%
119,532
ATNM icon
3163
Actinium Pharmaceuticals
ATNM
$25.1M
$387K ﹤0.01%
76,208
TG icon
3164
Tredegar Corp
TG
$276M
$385K ﹤0.01%
71,132
JYNT icon
3165
The Joint Corp
JYNT
$121M
$384K ﹤0.01%
39,998
INGN icon
3166
Inogen
INGN
$155M
$384K ﹤0.01%
69,941
+12,101
+21% +$63.9K
CMPX icon
3167
Compass Therapeutics
CMPX
$398M
$384K ﹤0.01%
246,012
-17,264
-7% -$29.9K
PDSB icon
3168
PDS Biotechnology
PDSB
$14.2M
$384K ﹤0.01%
77,203
WLFC icon
3169
Willis Lease Finance
WLFC
$1.16B
$384K ﹤0.01%
23,541
-1,764
-7% -$26.2K
ATRA icon
3170
Atara Biotherapeutics
ATRA
$80.3M
$382K ﹤0.01%
29,806
-1,936
-6% -$45.1K
CMT icon
3171
Core Molding Technologies
CMT
$227M
$382K ﹤0.01%
20,596
ESLT icon
3172
Elbit Systems
ESLT
$36.7B
$382K ﹤0.01%
1,789
+514
+40% +$104K
STKS icon
3173
The ONE Group
STKS
$58.4M
$381K ﹤0.01%
62,260
NREF
3174
NexPoint Real Estate Finance
NREF
$322M
$380K ﹤0.01%
24,144
EGRX
3175
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$378K ﹤0.01%
72,282
-38,072
-34% -$376K

Similar funds

Charles Schwab's Q4 2023 Portfolio in Review

As of Q4 2023, Charles Schwab held 3,619 positions worth $394B, up 13% from $349B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Trading was light in Q4 2023: portfolio turnover was 3.5%. Charles Schwab opened 44 new positions and exited 81, leaving the 3,619-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Financials and Healthcare.

  • Charles Schwab's largest Q4 2023 buy was Janus Henderson Mortgage-Backed Securities ETF: 7,612,323 shares worth $350M.
  • Charles Schwab added most to Merck in Q4 2023, an estimated $491M increase.
  • Charles Schwab's biggest Q4 2023 reduction was Novartis, cutting an estimated $409M.
  • Charles Schwab fully exited Activision Blizzard in Q4 2023, selling an estimated $343M.
  • Charles Schwab's ten largest holdings make up 19% of its $394B portfolio in Q4 2023.
  • Charles Schwab opened 44 new positions and closed 81 in Q4 2023.
  • Charles Schwab's portfolio value rose 13% quarter-over-quarter to $394B.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.